IN2014DN10899A - - Google Patents
Info
- Publication number
- IN2014DN10899A IN2014DN10899A IN10899DEN2014A IN2014DN10899A IN 2014DN10899 A IN2014DN10899 A IN 2014DN10899A IN 10899DEN2014 A IN10899DEN2014 A IN 10899DEN2014A IN 2014DN10899 A IN2014DN10899 A IN 2014DN10899A
- Authority
- IN
- India
- Prior art keywords
- mir
- abundance
- inhibiting
- expression
- provides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides chemically modified oligonucleotides capable of inhibiting the expression (e.g., abundance) of miR-15 family miRNAs, including miR-15a, miR-15b, miR-16, miR-195, miR-424, and miR-497. The invention provides in some embodiments, oligonucleotides capable of inhibiting, in a specific fashion, the expression or abundance of each of miR-15a, miR-15b, miR-16, miR-195, miR-424, and miR-497. The invention further provides pharmaceutical compositions comprising the oli gonucleotides, and methods of treating patients having conditions or dis orders relating to or involving a miR-15 family miRNA, such as a cardiovas cular condition. In various embodiments, the oligonucleotides provide ad vantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261662772P | 2012-06-21 | 2012-06-21 | |
US201361780352P | 2013-03-13 | 2013-03-13 | |
PCT/US2013/046960 WO2013192486A1 (en) | 2012-06-21 | 2013-06-21 | Inhibitors of the mir-15 family of micro-rnas |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN10899A true IN2014DN10899A (en) | 2015-09-11 |
Family
ID=49769409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN10899DEN2014 IN2014DN10899A (en) | 2012-06-21 | 2013-06-21 |
Country Status (17)
Country | Link |
---|---|
US (1) | US9163235B2 (en) |
EP (1) | EP2863956A4 (en) |
JP (1) | JP2015525081A (en) |
KR (1) | KR20150036140A (en) |
CN (1) | CN104540527A (en) |
AR (1) | AR091539A1 (en) |
AU (1) | AU2013277033A1 (en) |
BR (1) | BR112014032239A2 (en) |
CA (1) | CA2876105A1 (en) |
EA (1) | EA201590070A1 (en) |
HK (1) | HK1209621A1 (en) |
IN (1) | IN2014DN10899A (en) |
MD (1) | MD20150006A2 (en) |
MX (1) | MX2014015641A (en) |
SG (1) | SG11201408460UA (en) |
TW (1) | TW201406774A (en) |
WO (1) | WO2013192486A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9388408B2 (en) | 2012-06-21 | 2016-07-12 | MiRagen Therapeutics, Inc. | Oligonucleotide-based inhibitors comprising locked nucleic acid motif |
US10011833B2 (en) | 2013-03-15 | 2018-07-03 | MiRagen Therapeutics, Inc. | Bridged bicyclic nucleosides |
US10443044B2 (en) | 2014-04-17 | 2019-10-15 | Ips Heart | Generating cardiac progenitor cells from pluripotent stem cells using isoxazole or isoxazole like compounds |
JP6637961B2 (en) | 2014-08-04 | 2020-01-29 | ミラゲン セラピューティクス, インコーポレイテッド | MYH7B inhibitors and uses thereof |
MX2017001493A (en) | 2014-08-07 | 2017-05-09 | Regulus Therapeutics Inc | Targeting micrornas for metabolic disorders. |
JP2018503646A (en) | 2015-01-20 | 2018-02-08 | ミラゲン セラピューティクス, インコーポレイテッド | miR-92 inhibitors and uses thereof |
WO2017219170A1 (en) * | 2016-06-19 | 2017-12-28 | 毛侃琅 | Construction and application of lentiviral vector for specifically inhibiting human mirna-29a and mir-424 expression |
EP3548005A4 (en) | 2016-11-29 | 2020-06-17 | Puretech Health LLC | Exosomes for delivery of therapeutic agents |
CN106692175A (en) * | 2016-12-26 | 2017-05-24 | 大连医科大学附属第二医院 | Application of miR-665-3p inhibitor to preparation of medicine for preventing and treating ischemia-reperfusion injuries |
US10941403B2 (en) | 2018-04-02 | 2021-03-09 | Oregon Health & Science University | Microrna inhibitors as anti-cancer therapeutics |
JPWO2021020412A1 (en) | 2019-07-30 | 2021-02-04 | ||
CN116438305A (en) * | 2020-07-23 | 2023-07-14 | 法兰克福大学 | Combination inhibition of miRNAs for the treatment of heart failure |
CN113599540B (en) * | 2021-05-27 | 2023-05-23 | 山西医科大学 | Application of miRNA-195-5p in preparation of reagent for inhibiting or reducing nerve cell damage caused by aluminum maltol |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003029459A2 (en) | 2001-09-28 | 2003-04-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Micro-rna molecules |
WO2003093441A2 (en) | 2002-05-03 | 2003-11-13 | Duke University | A method of regulating gene expression |
US7892793B2 (en) | 2002-11-04 | 2011-02-22 | University Of Massachusetts | Allele-specific RNA interference |
AU2003291433B2 (en) | 2002-11-13 | 2008-05-22 | Thomas Jefferson University | Compositions and methods for cancer diagnosis and therapy |
US7482117B2 (en) | 2002-12-20 | 2009-01-27 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
CN1768139A (en) | 2003-02-10 | 2006-05-03 | 独立行政法人产业技术总合研究所 | Regulation of gene expression by DNA interference |
WO2005017111A2 (en) | 2003-07-15 | 2005-02-24 | The Trustees Of The University Of Pennsylvania | Methods and systems for identifying micro-rna targets and synthesizing novel micro-rnas and uses of the same |
EP1648914A4 (en) | 2003-07-31 | 2009-12-16 | Regulus Therapeutics Inc | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
US8106180B2 (en) | 2003-08-07 | 2012-01-31 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro RNAs |
WO2005017145A1 (en) | 2003-08-13 | 2005-02-24 | Japan Biological Informatics Consortium | Method of identifying or presuming gene under regulation regulated by functional rna and method of using the same |
EP1676914A4 (en) | 2003-09-22 | 2007-10-10 | Aichi Prefecture | Disease type of lymphoma and method of assessing prognosis |
JP2007512805A (en) | 2003-10-14 | 2007-05-24 | ノバルティス アクチエンゲゼルシャフト | Oligonucleotide microarray |
US20050182011A1 (en) | 2003-11-13 | 2005-08-18 | Eric Olson | Inhibition of TRP channels as a treatment for cardiac hypertrophy and heart failure |
KR100860087B1 (en) | 2003-12-15 | 2008-09-25 | 포천중문의과대학교 산학협력단 | Novel mirna molecules isolated from human embryonic stem cell |
US20050256072A1 (en) | 2004-02-09 | 2005-11-17 | University Of Massachusetts | Dual functional oligonucleotides for use in repressing mutant gene expression |
EP2295604B1 (en) | 2004-02-09 | 2015-04-08 | Thomas Jefferson University | Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features |
AU2005214904B2 (en) | 2004-02-13 | 2011-07-21 | Rockefeller University | Anti-microRNA oligonucleotide molecules |
US8088902B2 (en) | 2004-04-05 | 2012-01-03 | The Rockefeller University | DNA virus microRNA and methods for inhibiting same |
US20060134639A1 (en) | 2004-04-06 | 2006-06-22 | Huffel Christophe V | Method for the determination of cellular transcriptional regulation |
US20050260648A1 (en) | 2004-04-06 | 2005-11-24 | Huffel Christophe V | Method for the determination of cellular transcriptional |
ES2380923T3 (en) | 2004-04-07 | 2012-05-21 | Exiqon A/S | Small interfering microRNA and RNA quantification procedures |
EP2290071B1 (en) | 2004-05-28 | 2014-12-31 | Asuragen, Inc. | Methods and compositions involving microRNA |
CA2576233C (en) | 2004-08-10 | 2016-03-15 | Alnylam Pharmaceuticals, Inc. | Conjugate comprising an antagomir and a ligand |
DK1797183T3 (en) | 2004-09-02 | 2012-10-01 | Univ Yale | REGULATION OF ONCOGENES WITH MICRORNAS |
FR2877350B1 (en) | 2004-11-03 | 2010-08-27 | Centre Nat Rech Scient | IDENTIFICATION AND USE OF miRNAs INVOLVED IN THE DIFFERENTIATION OF CELLS FROM MYELOID LEUKEMIA |
WO2006137941A2 (en) | 2004-11-12 | 2006-12-28 | Ambion, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
WO2006063356A1 (en) | 2004-12-10 | 2006-06-15 | Isis Phamaceuticals, Inc. | Regulation of epigenetic control of gene expression |
US20060185027A1 (en) | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
US20060166920A1 (en) | 2005-12-27 | 2006-07-27 | Regents Of The University Of Michigan | Oligonucleotide based therapeutics |
EP1838870A2 (en) | 2004-12-29 | 2007-10-03 | Exiqon A/S | NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs |
US8071306B2 (en) | 2005-01-25 | 2011-12-06 | Merck Sharp & Dohme Corp. | Methods for quantitating small RNA molecules |
US20070065840A1 (en) | 2005-03-23 | 2007-03-22 | Irena Naguibneva | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS |
JP2006292367A (en) | 2005-04-05 | 2006-10-26 | Mitsubishi Rayon Co Ltd | Microarray for detecting mirna |
WO2006108582A2 (en) | 2005-04-15 | 2006-10-19 | Cenix Bioscience Gmbh | Human marker genes and agents for diagnosis, treatment and prophylaxis of cardiovascular disorders and artherosclerosis |
US9085774B2 (en) | 2005-04-19 | 2015-07-21 | Basf Plant Science Gmbh | Methods controlling gene expression |
PL2002003T3 (en) | 2005-05-27 | 2016-06-30 | Ospedale San Raffaele Srl | Gene vector comprising mi-rna |
CA2610265A1 (en) | 2005-05-31 | 2007-05-10 | Cold Spring Harbor Laboratory | Methods for producing micrornas |
US20070054287A1 (en) | 2005-05-31 | 2007-03-08 | Applera Corporation | Method for identifying medically important cell populations using micro rna as tissue specific biomarkers |
US20090209621A1 (en) | 2005-06-03 | 2009-08-20 | The Johns Hopkins University | Compositions and methods for decreasing microrna expression for the treatment of neoplasia |
EP1919512B1 (en) | 2005-08-10 | 2014-11-12 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides for use in modulating micro rna and uses thereof |
US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
CN101426912A (en) | 2005-08-17 | 2009-05-06 | 瑟纳治疗公司 | Chemically modified short interfering nucleic acid molecules that mediate RNA interference |
JP2009507918A (en) | 2005-09-12 | 2009-02-26 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | Compositions and methods for diagnosis and therapy of BCL2-related cancers |
US20070092882A1 (en) | 2005-10-21 | 2007-04-26 | Hui Wang | Analysis of microRNA |
JP2009516518A (en) | 2005-11-21 | 2009-04-23 | ジヨンソン・アンド・ジヨンソン・リサーチ・ピーテイワイ・リミテツド | Multi-targeting interfering RNAs with two active strands and methods for their design and use |
US20070259827A1 (en) | 2006-01-25 | 2007-11-08 | University Of Massachusetts | Compositions and methods for enhancing discriminatory RNA interference |
EP1986609A2 (en) | 2006-01-26 | 2008-11-05 | University of Massachusetts | Rna silencing agents for use in therapy and nanotransporters for efficient delivery of same |
WO2007092181A2 (en) | 2006-01-26 | 2007-08-16 | Unversity Of Massachusetts | Compositions and methods for modulating translational repression |
EP2388328A1 (en) | 2006-01-27 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of micrornas |
WO2007095387A2 (en) | 2006-02-17 | 2007-08-23 | Dharmacon, Inc. | Compositions and methods for inhibiting gene silencing by rna interference |
EP2522747A1 (en) | 2006-03-02 | 2012-11-14 | The Ohio State University | MicroRNA expression profile associated with pancreatic cancer |
CA2649045C (en) * | 2006-04-03 | 2019-06-11 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
US20080220423A1 (en) | 2006-05-19 | 2008-09-11 | Soren Moller | Oligonucleotide probes useful for detection and analysis of microRNA precursors |
WO2007147067A2 (en) | 2006-06-14 | 2007-12-21 | Rosetta Inpharmatics Llc | Methods and compositions for regulating cell cycle progression |
US20090307788A1 (en) | 2006-06-19 | 2009-12-10 | Kobenhavns Universitet | Ribozyme mediated stabilization of polynucleotides |
WO2008024499A2 (en) | 2006-08-25 | 2008-02-28 | Duke University | Methods for in vivo identification of endogenous mrna targets of micrornas |
CA2663962A1 (en) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention |
WO2008042231A2 (en) | 2006-09-29 | 2008-04-10 | Children's Medical Center Corporation | Compositions and methods for evaluating and treating heart failure |
EP2489742A1 (en) | 2006-10-09 | 2012-08-22 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) for the diagnosis and treatment of heart diseases |
WO2008147430A2 (en) | 2006-10-11 | 2008-12-04 | Nucleonics, Inc. | Microrna-formatted multitarget interfering rna vector constructs and methods of using the same |
US20100021914A1 (en) | 2006-11-23 | 2010-01-28 | Querdenker Aps | Oligonucleotides for modulating target rna activity |
CA2671302A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mirna regulated genes and pathways as targets for therapeutic intervention |
WO2008073921A2 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mir-126 regulated genes and pathways as targets for therapeutic intervention |
CA2671294A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mir-21 regulated genes and pathways as targets for therapeutic intervention |
AU2007333109A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Functions and targets of let-7 micro RNAs |
US20090137504A1 (en) | 2006-12-21 | 2009-05-28 | Soren Morgenthaler Echwald | Microrna target site blocking oligos and uses thereof |
EP3536788A1 (en) | 2006-12-21 | 2019-09-11 | QIAGEN GmbH | Microrna target site blocking oligos and uses thereof |
CA2671270A1 (en) | 2006-12-29 | 2008-07-17 | Asuragen, Inc. | Mir-16 regulated genes and pathways as targets for therapeutic intervention |
US20080287383A1 (en) | 2007-03-02 | 2008-11-20 | Nastech Pharmaceutical Company Inc. | Nucleic acid compounds for inhibiting erbb gene expression and uses thereof |
US9043994B2 (en) | 2007-03-13 | 2015-06-02 | Massachusetts Institute Of Technology | Cre-lox based gene knockdown constructs and methods of use thereof |
AU2008232316A1 (en) | 2007-03-26 | 2008-10-02 | Newcastle Innovation Limited | Therapeutic targets and molecules |
CA2687336C (en) | 2007-05-23 | 2014-12-23 | Dharmacon, Inc. | Micro-rna scaffolds and non-naturally occurring micro-rnas |
WO2009012263A2 (en) | 2007-07-18 | 2009-01-22 | The Trustees Of Columbia University In The City Of New York | Tissue-specific micrornas and compositions and uses thereof |
WO2009012468A2 (en) | 2007-07-18 | 2009-01-22 | The Regents Of The University Colorado | Differential expression of micrornas in nonfailing versus failing human hearts |
US20090092980A1 (en) | 2007-07-20 | 2009-04-09 | Christoph Arenz | miRNA PROCESSING INHIBITOR EFFICACY ASSAYS AND SUBSTANCES |
WO2009044895A1 (en) | 2007-10-03 | 2009-04-09 | Kyowa Hakko Kirin Co., Ltd. | Composition inhibiting the expression of target gene |
WO2009043353A2 (en) | 2007-10-04 | 2009-04-09 | Santaris Pharma A/S | Micromirs |
CA2704056A1 (en) | 2007-10-29 | 2009-05-07 | University Of Massachusetts | Encapsulated nanoparticles for nucleic acid delivery |
WO2009058818A2 (en) | 2007-10-29 | 2009-05-07 | The Board Of Regents Of The University Of Texas System | Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling |
EP2219653B1 (en) | 2007-11-09 | 2016-12-21 | The Board of Regents of The University of Texas System | Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair |
US8404659B2 (en) | 2008-03-07 | 2013-03-26 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of MicroRNA related diseases |
EP2279267A4 (en) | 2008-03-27 | 2012-01-18 | Vascular Biosciences Inc | Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases |
EP2105145A1 (en) | 2008-03-27 | 2009-09-30 | ETH Zürich | Method for muscle-specific delivery lipid-conjugated oligonucleotides |
US20090326049A1 (en) | 2008-04-04 | 2009-12-31 | Alexander Aristarkhov | Blocking oligos for inhibition of microrna and sirna activity and uses thereof |
US20100113284A1 (en) | 2008-04-04 | 2010-05-06 | Alexander Aristarkhov | Small interfering rna (sirna) target site blocking oligos and uses thereof |
EP2990487A1 (en) | 2008-05-08 | 2016-03-02 | Asuragen, INC. | Compositions and methods related to mirna modulation of neovascularization or angiogenesis |
CA2726052A1 (en) | 2008-06-04 | 2009-12-10 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small rna targeting of gene promoters |
WO2010036939A2 (en) | 2008-09-26 | 2010-04-01 | University Of Southern California | A system for synergistic expression of multiple small functional rna elements |
EP2358398A2 (en) | 2008-10-24 | 2011-08-24 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
WO2010126355A1 (en) | 2009-04-29 | 2010-11-04 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure |
CN102803284B (en) | 2009-06-08 | 2015-11-25 | 米拉根医疗公司 | For the chemically modified motif of miRNA inhibitor and stand-in |
-
2013
- 2013-06-19 US US13/921,537 patent/US9163235B2/en not_active Expired - Fee Related
- 2013-06-21 MD MDA20150006A patent/MD20150006A2/en not_active Application Discontinuation
- 2013-06-21 CN CN201380039961.7A patent/CN104540527A/en active Pending
- 2013-06-21 BR BR112014032239A patent/BR112014032239A2/en not_active IP Right Cessation
- 2013-06-21 JP JP2015518597A patent/JP2015525081A/en active Pending
- 2013-06-21 EP EP13806131.2A patent/EP2863956A4/en not_active Withdrawn
- 2013-06-21 AU AU2013277033A patent/AU2013277033A1/en not_active Abandoned
- 2013-06-21 EA EA201590070A patent/EA201590070A1/en unknown
- 2013-06-21 IN IN10899DEN2014 patent/IN2014DN10899A/en unknown
- 2013-06-21 KR KR1020157001535A patent/KR20150036140A/en not_active Application Discontinuation
- 2013-06-21 MX MX2014015641A patent/MX2014015641A/en unknown
- 2013-06-21 TW TW102122289A patent/TW201406774A/en unknown
- 2013-06-21 SG SG11201408460UA patent/SG11201408460UA/en unknown
- 2013-06-21 WO PCT/US2013/046960 patent/WO2013192486A1/en active Application Filing
- 2013-06-21 CA CA2876105A patent/CA2876105A1/en not_active Abandoned
- 2013-06-24 AR ARP130102219 patent/AR091539A1/en unknown
-
2015
- 2015-10-22 HK HK15110356.0A patent/HK1209621A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2876105A1 (en) | 2013-12-27 |
KR20150036140A (en) | 2015-04-07 |
SG11201408460UA (en) | 2015-01-29 |
WO2013192486A1 (en) | 2013-12-27 |
AR091539A1 (en) | 2015-02-11 |
HK1209621A1 (en) | 2016-04-08 |
BR112014032239A2 (en) | 2017-08-01 |
CN104540527A (en) | 2015-04-22 |
AU2013277033A1 (en) | 2015-01-22 |
EP2863956A1 (en) | 2015-04-29 |
EP2863956A4 (en) | 2016-01-20 |
MD20150006A2 (en) | 2015-06-30 |
MX2014015641A (en) | 2015-07-14 |
US9163235B2 (en) | 2015-10-20 |
EA201590070A1 (en) | 2015-04-30 |
TW201406774A (en) | 2014-02-16 |
US20130345288A1 (en) | 2013-12-26 |
JP2015525081A (en) | 2015-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN10899A (en) | ||
MX2013005875A (en) | Microrna inhibitors comprising locked nucleotides. | |
MX2021009118A (en) | Compositions and methods for inhibiting expression of the alas1 gene. | |
UA117098C2 (en) | Microrna compounds and methods for modulating mir-21 activity | |
PH12017501501A1 (en) | Compositions and methods for inhibiting expression of tmprss6 gene | |
MX2021015290A (en) | Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes. | |
NZ797319A (en) | Modified rnai agents | |
MX2019006413A (en) | Serpinc1 irna compositions and methods of use thereof. | |
MX355408B (en) | Oligonucleotide-based inhibitors comprising locked nucleic acid motif. | |
UA115652C2 (en) | Microrna compounds and methods for modulating mir-21 activity | |
WO2012142313A3 (en) | Micro-rna inhibitors and their uses in disease | |
WO2012024396A3 (en) | Compositions and methods for delivering nucleic acid molecules and treating cancer | |
MX2022001017A (en) | Compositions and methods for inhibiting expression of the alas1 gene. | |
AR083445A1 (en) | siRNA AGAINST FIBROSIS | |
MX2018006445A (en) | Il-34 antisense oligonucleotides and methods of using same. | |
MX368084B (en) | Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions. | |
PL398796A1 (en) | The use of miRNA molecules and antagomir for miRNA in the diagnosis, prevention and treatment of multiple sclerosis | |
NZ776080A (en) | Modified rnai agents | |
NZ728207A (en) | Oligonucleotide-based inhibitors comprising locked nucleic acid motif | |
TW201129365A (en) | Compositions and methods for inhibiting expression of IKK2 genes |